Trial Profile
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; PDS 0301 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMBO
- Sponsors EMD Serono
- 15 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 20 May 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2019 Planned number of patients changed from 185 to 106.